Therefore, the patients with ER+/PR− phenotype belonging to non-luminal-like IBC should also be identified and more effective treatments should be performed on them, such as cyclin-dependent kinase 4/6 inhibitors. The gene discussed is ESR1; the disease is inflammatory breast carcinoma.